ASO Therapy
ASO stands for antisense oligonucleotide. An ASO is a short, designed strand of nucleic acid that binds to a specific RNA message inside the body. Depending on how it is designed, an ASO may reduce a harmful RNA, change splicing, increase production from a working gene copy, or alter how a protein is made. ASOs are not the same as gene therapy: they usually act at the RNA level and often require repeat dosing.
Why it matters
ASOs are one of the most important platforms in rare disease medicine because they can sometimes be designed for very specific genetic mechanisms, including disorders that may not be a good fit for classic gene replacement.
Related content
What Is ASO Therapy?
ASO therapy uses short pieces of synthetic genetic material to change how RNA is read, processed, or reduced inside cells.
What AI Drug Discovery Could Mean for Rare Disease Families
AI drug discovery is entering a new phase: not just better software, but a new industrial stack linking frontier models, pharma data, robotics, and real experiments.
Why it matters: Rare disease research often starts with small datasets, limited funding, urgent timelines, and difficult trial design. AI-linked discovery systems could help researchers generate stronger candidates and better experiments faster, but families should watch for clinical validation, access, manufacturing, and clear evidence rather than hype.
Source: GENEration Hope editorial analysis